Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 1R01DA054347 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute on Drug Abuse (NIDA) | NIH |
Not provided
Not provided
Not provided
Not provided
This study plans to enroll participants with opioid use disorder who are not currently seeking treatment to assess the effects of cannabis on opioid withdrawal and other related outcomes.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intranasal Opioid Agonist | Experimental | Participants will receive non-therapeutic, experimental doses of an opioid agonist or placebo. Active opioid agonist/placebo will be administered once per session and will be administered intransally (snorting). |
|
| Vaporized cannabis | Experimental | Participants will receive non-therapeutic, experimental doses of active or placebo vaporized cannabis. Active cannabis/placebo will be administered once per session and will be administered via a vaporizer. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Inhaled vaporized cannabis | Drug | Double-blind cannabis and placebo doses, administered through vaporizer |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change from Baseline - Opioid Withdrawal Severity - Visual Analog Scale (VAS) | Subjective ratings of opioid withdrawal severity on visual analog scale (scale 0-100; 0 = not at all, 100 = extremely) | Change from baseline |
| Measure | Description | Time Frame |
|---|---|---|
| Change from Baseline - Opioid Drug Liking - Visual Analog Scale (VAS) | Subjective ratings of drug liking on visual analog scale (scale 0-100, 0 = not at all, 100 = extremely) | Change from baseline |
| Change from Baseline - Respiration |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Paul Nuzzo, MA | Contact | 859-323-0002 | pnuzz2@email.uky.edu |
| Name | Affiliation | Role |
|---|---|---|
| Shanna Babalonis, PhD | University of Kentucky | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Center on Drug and Alcohol Research | Recruiting | Lexington | Kentucky | 40508 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009293 | Opioid-Related Disorders |
| ID | Term |
|---|---|
| D000079524 | Narcotic-Related Disorders |
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Intransal opioid | Drug | Double-blind opioid and placebo doses, administered intranasal route |
|
Physiological monitoring of respiration rate (breaths per minute)
| Change from baseline |